Biocon Stock

Barring Sun Pharmaceutical Industries, which is anticipated to rally up to 10 per cent; other stocks indicate weak bias, as per technical charts

This, even as revenues rise 36% and Ebitda is up 35%

Biocon share may slip up to 21 per cent if breaks 52-week low

Bengaluru-based Biocon had in September 2022 sold a 5.4% stake in the open market, as per an exchange filing

Stocks to Watch Today: According to reports, Zomato is likely to witness a block deal on Wednesday.

Biocon's core Ebitda came in at Rs 816 crore, up 34 per cent

Stocks to watch today: Biocon received 11 observations in Form 483 for their Bengaluru and Mayalsia facilities from the USFDA; Ashok Leyland won orders from major fleets for 1,400 school buses in UAE.

Stock market LIVE updates: The broader markets suffered more losses than the frontline indices. The BSE MidCap and SmallCap indices shed 0.5 and 0.7 per cent, respectively.

Stocks to watch today: HDFC, slated to merge with HDFC Bank, raised Rs 4,000 crore through a paper with a maturity of 21 months; Jet Airways plans to lease 6 to 8 planes as part of re-launch.

CLOSING BELL: The Nifty IT, Bank, and FMCG indices dropped over 1 per cent each

CLOSING BELL: Sectorally, the broad-based rally saw the Nifty Auto index ending with 2-per cent gain, and the Nifty Metal index with 1.6-per cent rally

Shares of Zomato face stiff resistance at Rs 78, while the downside support stays at Rs 60

At 10:26 AM, the stock of Biocon was down 3 per cent at Rs 316.10, as compared to 1 per cent decline in the S&P BSE Sensex

Alembic Pharma and Dr Reddy's Labs plunged 12% and 11%, respectively in intra-day trade post their June quarter results

Pharma major Dr Reddy's Laboratories (DRL) expects the Russian coronavirus vaccine Sputnik V to get approval from the Indian regulator in the next few weeks, a company official has said

Analysts prefer stocks trading above the 200-DMA, since they tend to perform better in a trending market. Risk management, hence, becomes comparatively easier

Due to professional differences with the chairperson on strategic priorities and the vision for the company, Dr Christiane Hamacher has stepped down as the MD of Biocon Biologics

3i Infotech Ltd has entered into definitive agreements to sell its software products business to the funds advised by Apax Partners for Rs 1,000 crore

Launch of a cancer drug was delayed due to Covid-19

The company said profitability was impacted on account of higher R&D expenses, staff costs, other expenses and forex losses